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Summary Recent studies suggest a high specificity of "mTc-galactosyl neoglycoalbumin (99mTc-NGA) receptor
scanning in vivo by providing both morphological and functional diagnosis of liver disease. In 22 patients with
advanced breast cancer SSmTc-NGA (150 MBq; 50 nmol) was exclusively trapped by the liver, the images
showing 'cold spots' in areas of liver metastases formation. A two-tailed analysis was performed: the time
activity curves recorded for the liver and precordial area were subjected to a kinetic receptor-calculating model
allowing an estimation of the NGA-receptor concentration of the liver (i.e. hepatic binding protein, HBP) as
well as calculation of the residual functional liver volume (RFLV) via the S.P.E.C.T.-study. In breast cancer
patients with liver metastases a significantly (P<0.01) lower HBP-concentration was estimated (0.65 ± 0.16 vs
0.82 ± 0.17 gimol I') as evidenced by a lower 99mTc-NGA-accumulation in the liver resulting also in a
significantly (P<0.001) lower RFLV (739 ± 348 vs 1336 ± 184 ml). In four amonafide-treated patients
(800 mg m-2 intravenous infusion over 3 h) approximately one week after one chemotherapy cycle a significant
(P<0.05) increase in HBP-concentration (0.56 ± 0.10 vs 0.72 ± 0.06 Lmoll-) of the liver was found corres-
ponding with an increase in RVLF (546 ± 297 vs 670 ± 265 ml). These regulatory mechanisms at the HBP
level measured in vivo provide further evidence that 99'Tc-NGA should have promise as a clinically useful
receptor radiopharmaceutical for both quantification of liver function and assessment of liver mor-
phology.
One of the most challenging fields in nuclear medicine is the
use of specific receptor radiopharmaceuticals (Eckelman et
al., 1979). These tracers have been successfully applied in
oncology, such as for the detection of endocrine tumours
using somatostatin analogs (Krenning et al., 1989), specific
receptor radiotracers for the brain (Wagner et al., 1983),
radiolabelled epidermal growth factor in gynaecology (Schat-
ten et al., 1990), radiolabelled oestrogen analogs in breast
cancer (Pavlik et al., 1990) or galactose-terminated neog-
lycoalbumin (NGA) in primary and secondary liver cancer
(Virgolini et al., 1989b). 9'Tc-NGA is one of the first
chemically synthetised receptor radiopharmaceuticals intro-
duced for in vivo use in humans (Vera et al., 1984; Stadalnik
et al., 1985; Virgolini et al., 1989a,b, 1991, 1992). It is a
glycoprotein with galactose residues which upon injection
into the bloodstream is exclusively trapped by hepatocytes on
the basis of specific interaction with the cell surface-bound
hepatic binding protein (HBP) (Stockert & Morell, 1983).
Preclinical studies have confirmed the receptor-binding pro-
perties of 99'Tc-NGA (Virgolini et al., 1989a). The unique
specific interaction of NGA with HBP provided the basis of
kinetic modelling (Vera et al., 1985; 1991a). Hence, the
simulation of 9'9Tc-NGA binding onto hepatocytes was
extended to patients with various liver disease (Stadalnik et
al., 1985; Virgolini et al., 1991, 1992). In these studies hepatic
function was determined from global HBP-receptor density
and hepatic blood flow Q. Changes in either of these two
independent physiologic parameters are reflected by the rate
of hepatic accumulation. Delivery of 9'Tc-NGA is deter-
mined by the magnitude of the hepatic blood flow Q, and the
rate of the HBP-mediated binding process is governed by the
affinity of 99'Tc-NGA for the receptor and by HBP-
concentration. Thus, changes in hepatic blood flow Q or
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HBP-concentration will be reflected by the liver time-activity
curves. The approach has been successfully applied as a new
technique for assessment of functional liver cell mass (in
addition to liver morphological S.P.E.C.T.-scintigraphy) in
patients with hepatocellular carcinoma (Virgolini et al.,
1989b), liver cirrhosis and fibrosis (Virgolini et al., 1991),
viral hepatitis (Virgolini et al., 1992), and in patients under-
going liver transplantation (Woodle et al., 1987).
A decade ago direct evidence for reduction of HBP-
concentration as a consequence of hepatocellular pathology
was reported by Stockert and Becker (1980). We also found a
reduced HBP-concentration in patients with primary or
secondary hepatic cancer in vivo and in vitro (Virgolini et al.,
1989a,b). This study now investigated the in vivo binding of
99'Tc-NGA to HBP in patients with advanced breast cancer
with and without liver metastases. The results suggest that
serial studies may document changes in hepatocellular func-
tion in patients undergoing chemotherapy for breast cancer.
Materials and methods
Subjects
The application of NGA to humans was approved by the
Ethical Committee of the Faculty of Medicine, University of
Vienna. All patients reported here were women and had
histologically documented advanced breast cancer. 'Tc-
NGA-scintigraphic studies were performed as an addendum
to routine ultrasound, 99'Tc-sulfur colloid scintigraphy, com-
puted tomography and frequent laboratory examinations in
order to assess liver morphology and functional hepatic
mass. Seven women had no clinical evidence of liver meta-
stases, whereas the above mentioned clinical investigations
strongly suggested secondary involvement of the liver in 15
others.
In order to further evaluate the significance of the 9'Tc-
NGA-scintigraphy in patients with breast cancer, eight
women receiving palliative chemotherapy with amonafide
(nafidimide, benzisoquinoline-dione; Knoll AG, Ludwig-
shafen, Germany) in a Phase II clinical trial (Scheithauer et
al., 1991) were designed to undergo serial 9'Tc-NGA-
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scintigraphic studies. These patients had histologically
confirmed progressive advanced breast cancer, refractory to
prior hormone and/or first-line chemotherapy. Amonafide
was given intravenously at a starting dose of 800mgm-2
over 3 h. The schedule of drug administration was a single
drug infusion given every 28 days.
Radiopharmaceutical synthesis andlabelling
The synthesis and labelling of NGA was described in detail
previously (Virgolini et al., 1989a). D (+)-galactose was
acetylated with acetic anhydride to galactose-penta-acetate
which was brominated at Cl to aceto-bromo-galactose.
Aceto-bromogalactose was reacted with thiourea to
tetraacetyl-galactosylthiopseudourea, which, by reaction with
chloro-acetonnitrile, formed cyanomethyl-1,3,4,6-tetra-o-
acetyl-p-D-galactopyranoside (A). This intermediate was
purified by recrystallisation and analysed by 'H-NMR. A
solution of 0.1 mol 1` of (A) and 0.01 mol 1-' CH3ONa in
absolute methanol was kept at room temperature for 48 h
and then stored as stock solution at - 15°C (up to 3
months). It contained an average of 0.055 mol 1- 2-imino-2-
methoxyethyl-l-thio-p-D-galacto-pyranoside (B, coupling rea-
gent). A measured aliquot of this stock solution (125 ,ul;
0.055 mol 1`) was evaporated to dryness, redissolved in fresh
0.2 mol 1-' borate buffer, pH 8.6, a precise amount of human
serum albumin (HSA; 17y1, 20% HSA = 3.4 mg = 50 nmol;
Immuno AG, Vienna, Austria) was added and incubated
overnight at room temperature to produce the NGA-ligand.
This was routinely isolated by repetitive ultrafiltration
through a membrane with 20 kD exclusion limit separating
unbound coupling agent into the filtrate. The number of
galactose residues per HSA-molecule was synthetically con-
trolled by the molar ratio of coupling agent/HSA. A molar
ratio of coupling agent/HSA = 138 was employed, resulting
in about 21 galactose residues per HSA-molecule.
For each patient 3.5 mg NGA/patient (50 nmolml-') were
labelled with 9"Tc in 0.15 mol I-1 NaCl at pH 2.5 by adding
the desired activity of 91Tc04- (patient dose 150 MBq) and
reducing it with 32jig Sn++ generated in situ from a tin-
anode and Pt-cathode, by applying a d.c.-current of 5 mA for
11.4 s in 1 ml labelling volume. After stirring for 30 min, the
product was neutralised and finally filtered through a sterile
0.2Am membrane. Radiochemical purity was routinely moni-
tored by cellulose-acetate electrophoresis in 0.1 mol 1- bar-
bital buffer, pH 8.6, run at 300 V for 20 min. This system
offered the advantage of determining both free Tc04- and
reduced hydrolised Tc (TcO2 x H20) in single analysis.
Radiochemical purity was generally >97%, i.e. the "mTc-
NGA peak contained >97% of total 99mTc on the elect-
rophoresis strip. The labelling yield after filtration through
low-protein-absorption membranes amounted to about 95%,
in vitro-stability at room temperature exceeded through more
than 10 h.
Gamma camera imaging
In all patients, the in vivo-binding of99mTc-NGA to HBP was
estimated. The exact dose given to a patient amounted to
140 ± 15 MBq/3.5 mg NGA (50 nmol). The patients were
placed in a supine position under a gamma camera (Searle
Radiographics Inc., Des Plaines, IL) connected to a data
processor (PDP 11/34, Digital Equipment Int. Ltd., Galway,
Ireland). The gamma camera was equipped with a low energy
collimator (140 KeV; Searle, Radiographics, Inc.). Computer
acquisition of gamma-camera data was performed at a rate
of two frames/minute and a matrix of 64 x 64 pixels. Time-
activity curves were recorded over precordium and liver. The
total acquisition time was 30 min.
Two to 5 min after injection of99"Tc-NGA a blood sample
(1 ml) was drawn and transferred into a preweighed plastic
tube. The blood concentration of 99mTc-NGA was calculated
using the activity/gram of this blood sample and a diluted
standard of the labelled product (1:5000). The blood sample
was used to relate the counts measured under the gamma-
camera to the absolute amount of injected tracer.
After completion of the dynamic study ofNGA-uptake the
patients underwent a S.P.E.C.T.-examination of the liver
using a dual head rotating gamma-camera equipped with a
low energy collimator (ROTA-camera, Siemens GmbH,
Erlangen). Using a matrix of 128 x 128 pixels, 60 pictures
were obtained within a total exposure time of 10 min (angle
6°/1 turn 10 s).
Analyses
Gamma camera data (dynamic study)
The pharmacokinetics of NGA follow the model designed
and extensively validated by Vera et al., 1985, 1991a,b; Kudo
et al., 1991; Virgolini et al., 1989b, 1991a,b. It consists of the
hemodynamic subsystem which delivers the ligand to the
target organ, and of the receptor-binding subsystem in which
the formation of the receptor-ligand complex within the
target organ takes place. A further path allowing for the
utilisation of the ligand-receptor complex consists of the
unidirectional catabolic reaction of the complex into the
metabolic end product. Following this model, system state
equations can be obtained of the kinetic system which are
mathematically represented as a system of first order non-
linear differential equations. Further shown in the model are
two observers designated Y, and Y2. In practice, observer Y1
looks at the time course of radioactivity in the extrahepatic
blood which can be obtained by a region of interest over the
precordial area. Observer Y2 measures the radioactivity in the
area of the liver which is the sum of two components, the
radioactivity of the free ligand and the radioactivity of the
ligand-receptor complex.
The primary input data for the analysis of the kinetic
parameters are the time-activity curve of the radioactivity in
a region containing the liver representing Y2 of the model
and the time-activity curve obtained over a precordial region
representing YI. This data together with the blood count
results are entered into a program which estimates system
states and system parameters iteratively. The program runs
on a MicrovaxIl computer and produces as result both the
graphic representation of the experimental and the fitted
curves and additional numeric output of the system
parameters, the most important of which are the concentra-
tion of HBP in the liver and the forward binding rate con-
stant Kb for the reaction of the ligand with the receptor in
the liver. Furthermore, the program gives estimates on the
goodness of fit and of the errors for the various parameters.
It should be mentioned that even on a relatively fast com-
puter such as the Microvaxll the analysis for one patient
needs about half an hour of computing time.
Gamma camera (S.P.E.C.T.-study)
Transverse slices from the S.P.E.C.T.-study were used to
estimate the residual functional liver volume (RFLV). The
liver volume was determined by applying a fixed cutoff
threshold of 37% of the maximum pixel value. After
thresholding the number of pixels occupied by the liver was
computed. The procedure was carried out for each slice in
which the liver was visible after thresholding. All areas were
then added and multiplied by the pixel volume in order to
obtain the volume of the liver (given in ml). The pixel
dimensions in millimeters were obtained from distance cali-
bration measurements carried out regularly as part of the
quality control procedures for the gamma camera.
The thresholding method used to determine the liver
volume from the S.P.E.C.T. images measures the functional
liver volume insofar in that uptake values exceeding 37% are
considered as belonging to the functional liver tissue. The
thresholding technique implies that solid metastases within
the liver are excluded from the functional volume if they
exceed a diameter of 1 cm. This is related to the S.P.E.C.T.
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thresholding technique as such (Tauxe et al., 1982; Strauss et
al., 1984) is known to give accurate values especially for the
determination of liver volume due to negligible background
activity.
*The threshold used was determined empirically from phan-
tom experiments in preliminary studies. In those, a liver
phantom with a known volume of 650 ml was suspended in a
water tank of dimensions 40 x 40 x 20 cm. Water tank and
liver phantom were filled with radioactive solutions with
different ratios of concentrations and the threshold deter-
mined for which the measured liver volume was closest to the
true liver volume.
Statistical analysis
Statistical comparison between the means was made by the
Student's t-test for unpaired data at a confidence level of
95%. Weighted linear regression was used to calculate the
slope and y-intercept of each correlation plot during the
follow-up period. Values are presented as means + standard
deviations.
Results
Biodistribution
In vivo-simulation of 99mTc-NGA-kinetics allowed quantifi-
cation of9'Tc-NGA-binding to HBP. In both patients with
normal hepatic function (Virgolini et al., 1989b; Virgolini et
al., 1991, 1992) and patients with liver metastases 99nTc-NGA
was exclusively trapped by the liver. At 10 min after injection
liver uptake was >95% of the administered dose in patients
with normal livers. No significant difference was found for
patients with documented liver metastases. One hour after
injection of 99mTc-NGA the plasma activity ranged from 1 to
2%. At 24 h after injection, visible tracer accumulation
(about 30-50%) was found over the intestine showing that
the major excretory route for NGA is the biliary system. At
that time urinary excretion was <2% suggesting that the
stability of the receptor-radiopharmaceutical is such that
urinary excretion of degradation products is only minimal.
Binding ofNGA to HBP -simulation study
In the seven women without liver metastases (Table I) the
mean HBP concentration amounted to 0.82 ± 0.17 limol I`
which is in the lower range of the values estimated previously
in subjects with normal hepatic function (Virgolini et al.,
1989b; Virgolini et al., 1991, 1992). With the exception of one
patients (Table I, H.J.) a good matching of actual HBP-
values (dynamic study) with the estimated liver volume
(S.P.E.C.T.-study) as well as the laboratory values was
found. The forward binding rate constant Kb as well as the
hepatic blood flow Q were also in the lower normal
range.
In 15 women (Table II) ultrasound, 99Tc-sulfur colloid
scintigraphy, and/or computed tomography strongly sug-
Table I Breast cancer patients without liver metastases formation
Location of Chemotherapy Liver
Pat. Age metastases regimen HBP Kb Q volume
H.J. 64 B,L FU/LV/MMC 0.51 81 0.0262 1574
S.M. 74 S,B FU/LV/MMC 0.68 82 0.0314 1022
D.V. 54 B,L FU/LV/MMC 0.89 89 0.0225 1494
G.M. 49 B,L FU/LV/MMC 0.87 67 0.0312 1229
M.C. 72 B,L FU/LV/MMC 0.83 90 0.0383 1304
H.I. 54 B,S FU/LV/MMC 1.01 102 0.0296 1302
H.A. 47 B,S,N amonafide 0.92 89 0.0230 1432
x 59 0.82 85.7 0.0288 1336
s.d. 10.1 0.17 10.7 0.0055 184
HBP: 0.8-1.2.ltmoll 1; Kb: 80-l120Jmoll-'s-'; Q: 0.02-0.041s- . Liver
volume: ml; B: bone; L: lung; S: skin; N: lymph nodes. FU: 5-fluorouracil, LV:
leucovorin, MMC: mitomycin C.
Table II Breast cancer patients with liver metastases formation
Location of Chemotherapy Liver
Pat. Age metastases regimen HBP Kb Q volume
B.E. 63 B,L,H CMF 0.76 52 0.0198 691
H.I. 63 B,L,H CMF 0.35 54 0.0176 167
M.I. 62 B,L,H,N CMF 0.83 89 0.0231 672
G.A. 67 S,H,N CMF 0.73 82 0.0332 1121
F.M. 48 L,H mitoxantrone 0.75 47 0.0172 832
N.K. 57 B,L,H FU/LV,MMC 0.58 76 0.0231 1321
D.B. 61 B,L,H FU/LV/MMC 0.63 83 0.0232 n.e.
D.M. 82 B,L,H,N FU/LV/MMC 0.54 79 0.0221 642
B.H. 45 B,H amonafide 0.45 57 0.0191 349
L.H. 60 B,N,S,H amonafide 0.67 52 0.0231 254
M.A. 40 H,S amonafide 0.93 57 0.0302 n.e.
J.R. 41 H,L amonafide 0.87 76 0.0194 1189
B.E. 61 B,H amonafide 0.51 72 0.0283 691
R.E. 44 H amonafide 0.57 71 0.0212 789
P.M. 63 H amonafide 0.62 59 0.0182 892
x ± 57.1 0.65 67.1 0.0225 739
s.d. 11.5 0.16 13.6 0.0047 348
HBP: 0.8-1.2iimoll-; Kb: 80-12OgLmoll's-'; Q: 0.02-0.041s-'. Liver
volume: ml. n.e.: not estimated. B: bone; L: lung; H: liver; N: perlpheral iympn
nodes; S: skin; CMF: cyclophosphamide, metrotrexate, 5-fluorouracil, FU:
5-fluorouracil, LV: leucovorin, MMC: mitomycin C.552 I. VIRGOLINI et al.
gested the presence of liver metastases. These patients were
very heterogeneous with respect to the ongoing chemo-
therapy. Statistical analysis of the in vivo binding data
showed that the mean HBP-concentration was significantly
(P<0.01) lower for the women with mastectomy compared
with those without metastases amounting to 0.65 ± 0.16
ymol I'. Furthermore, the binding rate constant Kb was
significantly (P<0.05) lower indicating a weaker ability of
NGA-binding to the hepatocytes. No significant difference
was noted for hepatic blood flow Q between the two
groups.
In order to further evaluate the significance ofthese kinetic
and binding-data in human breast cancer, those women on
amonafide were supposed to be investigated during ongoing
chemotherapy in order to look at the effect of the drug, and
thus possible changes in NGA-binding behaviour that may
occur in vivo. Patients on amonafide were well documented
(Table III) running in a Phase II clinical trial (Scheithauer et
al., 1989). With respect to NGA-binding onto the
hepatocytes, those four (out of eight) patients in whom a
second scintigraphic evaluation could be performed showed
significant (P<0.05) increase in HBP-density under ongoing
therapy with amonafide (Table IV; 0.56 ± 0.10pmol 1l
before and 0.72 ± 0.06iLmol I' approximately 2 weeks after
a single chemotherapy cycle). In one patient (Table IV, B.H.)
initial HBP-increase was followed by a decrease after the
second amonafide cycle. In all patients a good correlation of
NGA-binding data with actual laboratory values for liver
function and clinical features was found.
Out of the seven patients on polychemotherapy with 5-
fluoro-uracil (FU)/leucovorin (LV)/mitomycin C (MMC)
only two could be monitored a second time (Table V). Again,
in both patients a small increase of HBP-density was
observed after one chemotherapy cycle.
Binding ofNGA to HBP -morphological study via S.P.E.C.T.
Liver morphology was studied by S.P.E.C.T.-scintigraphy. In
patients without liver metastases homogeneous uptake of
99'Tc-NGA by the liver was found. In those with liver metas-
tases small 'cold spots' presented the liver malignancy as
already reported previously (Virgolini et al., 1989b). All
9'Tc-NGA-images were comparable to conventional liver
images obtained by 9'9Tc-sulfur colloid. The estimated RFLV
was significantly (P<0.01) lower in patients with liver
metastases as compared with those without liver metastases
(739 ± 348 vs 1336 ± 184ml). Treatment with amonafide in-
creased the RFLV from 546 ± 297 to 670 ± 265 ml
(P = 0.07).
Discussion
Several receptor-binding radiopharmaceuticals have been
introduced for the in vivo evaluation of receptor density and
binding affinity (Eckelman et al., 1979; Krenning et al., 1989;
Wagner et al., 1983; Schatten et al., 1990; Pavlik et al., 1990;
Virgolini et al., 1989b), and a variety of nuclear medicine
techniques have been implemented to be useful in this aspect
(Wagner et al., 1983; Vera et al., 1985; 1991a; Farde et al.,
1986; Logan et al., 1987). A valid analytic assessment of
receptor biochemistry via kinetic modelling (Vera et al., 1985;
1991a) was applied for this study. As the use of S.P.E.C.T.
and P.E.T. increases in oncology, we obtained the
S.P.E.C.T.-quantified residual functioning liver volume
(RFLV) for a comparative evaluation of 99mTc-NGA-
uptake.
The results obtained in this study suggest that 99"Tc-NGA
kinetic imaging as well as S.P.E.C.T.-imaging may provide a
new noninvasive means for the diagnosis of metastatic liver
cancer. The methodology could provide valuable data not
only for the morphological diagnosis but also for the extent
of metastases formation in the human liver, and thus residual
functional liver cell mass. The more infiltrated the liver the
lower the estimated NGA-receptor (i.e. HBP) concentration,
or, the RFLV. Those patients without liver metastases (Table
I) had a higher HBP concentration estimated from the time
activity curves as well as a higher S.P.E.C.T.-estimated
RFLV as compared with those patients with liver metastases
(Table II). In general, a good correlation between S.P.E.C.T.-
estimated RFLV and dynamic imaging of NGA-binding was
found. However, in one patient (H.J., Table I) with a
relatively low HBP concentration of 0.51 iLmol 1', a
relatively high RFLV of 1574ml was calculated. The mean-
Table HI Clinical data of the patients undergoing treatment with
amonafide
Number of
Pat. Therapy prior treatment
to amonafide cycles Therapeutic response
B.H. Hormonal
radiotherapy
FU/LV/MMC x 5
L.H. Hormonal
CMF x 2
H.G. Hormonal
radiotherapy
FU/LV/MMC x 2
M.A. Radiotherapy
CMF x 3
J.R. Hormonal
CMF x 5,
FAC x 2
B.E. Hormonal
radiotherapy
FU/LV/MMC x 4
R.E. Hormonal
FAC x 6
P.M. Hormonal
FU/LV/MMC x 3
3 PR for 3 months,
survival 5.5 months
6
2
s.d. for 5 months,
survival + 19 months
s.d. for 4.5 months,
survival for + 11 months
2 PD after 2 months,
survival 4 months
2 PD after 2 months,
survival 2.5 months
4
3
Clinical response,
discontinued because of
cardiotoxicity
s.d. for 8 months,
survival + 30 months
s.d. for 5 months,
survival 9 months
Patients received amonafide (800 mgm-2) every 4 weeks. PR:
partial regression, s.d.: stable disease; PD: progressive disease
location of metastases see Table 11. CMF: cyclophosphamide,
metrotexate, 5-fluorouracil; FAC: 5-fluorouracil, doxorubicin,
cyclophosphamide; FU: 5-fluorouracil; LV: leucovorin; MMC:
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Table IV HBP, Kb, Q and laboratory values in amonafide-treated patients
Pat. Cycle
B.H. Before 1st
After 2 wks
Before 3rd
HBP
0.45
0.76
0.52
Kb
57
86
62
Q
0.0191
0.0232
0.0123
Liver
volume
349
621
322
Bili
1.5
0.4
2.2
AP
420
303
319
AST
39
16
32
ALT
27
8
21
LDH
221
323
272
L.H. Before 2nd 0.67 52 0.0231 254 0.5 328 34 35 356
After 2 wks 0.74 67 0.0252 327 0.5 343 13 16 270
H.A. Before 1st 0.92 89 0.0230 1432 0.7 264 23 32 488
M.A. Before 1st 0.93 57 0.0302 n.e. 0.7 308 25 48 997
J.R. Before 2nd 0.87 76 0.0194 1189 0.8 437 25 28 410
B.E. Before 1st 0.51 72 0.0283 691 1.0 410 43 52 273
After 2 wks 0.62 79 0.0282 781 0.8 306 33 29 253
R.E. After 3rd 0.57 71 0.0212 789 0.6 73 10 11 187
P.M. Before 1st 0.62 59 0.0182 892 1.1 85 25 33 265
After 4 wks 0.74 62 0.0169 952 1.1 87 32 29 273
Before: x (n = 4)
± s.d.
After: x (n = 4)
± s.d.
0.56 60 0.0221 546 1.03 310 35 37 278
0.10 8 0.0462 297 0.41 156 7 11 56
0.72* 73 0.0233 670 0.70* 259 23* 20* 279
0.06 11 0.0473 265 0.32 116 10 10 30
HBP: 0.8 1.2 jtmol I -'; Kb: 80-120 l2 mol 1-'s-'; Q: 0.02-0.041s-'; bilirubicin:
0.15-1.0 mgdl-'; alkaline phosphatase: 70-170 U l-'; AST: 5-17 U lI'; ALT: 5-23 U I-'; LDH:
80-240 U 1- ; liver volume in ml. n.e. = not estimated; *P = 0.05 before and after one amonafide
cycle. Women on amonafide were supposed to be investigated during ongoing chemotherapy (every
4 weeks 800 mg m-2). In four women a second evaluation could be performed showing an increase
of HBP-density after the 1st chemotherapy cycle. Increase of HBP-concentration was accompanied
by a decrease of (laboratory) abnormal liver function tests.
Table V HBP, Kb, Q and laboratory values in FU/LV/MMC-treated
patients
Time of
measurement Liver
Pat. (cycle) HBP Kb Q Volume
H.J. After 4th 0.51 81 0.0262 1574
S.M. Before 2nd 0.68 82 0.0314 1022
After 2nd 0.74 85 0.0321 1131
D.V. Before 3rd 0.77 79 0.0225 994
After 3rd 0.89 85 0.0302 1008
H.I. After 5th 1.01 102 0.0296 1302
N.K. Before 4th 0.58 76 0.0231 1321
D.B. Before 3rd 0.63 83 0.0232 n.e.
D.M. After 3rd 0.54 69 0.0221 642
HBP: 0.8-1.2jamoll'; Kb: 80-120OLmoll-' s';
0.041 s 1; Liver volume: ml; n.e. = not estimated.
fluorouracil; LV: leucovorin; MMC: mitomycin C.
Q: 0.02-
FU: 5-
ing of this discrepancy is not clear, but it could be speculated
that at the time of imaging the predictive value for HBP
concentration which summarises global hepatic function (Vir-
golini et al., 1991) was already low when laboratory values
and S.P.E.C.T.-estimated RFLV were still high.
The significance of NGA-binding to the liver was also
evaluated in patients undergoing chemotherapy. The possi-
bility of recovery of liver function to at least some extent
under palliative chemotherapy with the investigational agent
amonafide (Scheithauer et al., 1991) shows that the technique
applied is sensitive enough to measure changes in HBP recep-
tor density in vivo. In Phase I clinical trials in patients with
prostatic carcinoma (Craig et al., 1989) and in Phase II
studies in advanced breast cancer (Scheithauer et al., 1991;
Constanze et al., 1989) amonafide was shown to be an active
drug with therapeutic potential. When applied to humans the
dose limiting toxicity observed was myelosuppression, with
rapid recovery from granulocytopenia and thrombocytopenia
allowing a 3- to 4-week drug administration schedule. In our
study increase in HBP was observed approximately 2 weeks
after one chemotherapy cycle. This increase was well matched
with actual laboratory values for hepatic function. As
amonafide is a DNA intercalating agent (Waring et al., 1979)
which inhibits protein and nucleotide synthesis (Andersson et
al., 1987) the basis for an increase of HBP-concentration
could not be de-novo synthesis of receptor protein. As we
observed no effect of amonafide on hepatic blood flow Q a
direct action of the drug on the receptor binding subsystem
seems to be close. One explanation for an increased HBP
density after therapy with amonafide could also be the recyc-
ling of HBP to the cell surface which has been shown in in
vitro studies (Steer & Ashwell, 1980) previously. This could
result in an increased binding of 9'9Tc-NGA onto the
hepatocytes. Circulating binding inhibitors (Marshall et al.,
1978) that are present in the plasma of patients with car-
cinomas could be altered by administration of amonafide.
The observed increase of the affinity constant Kb could also
mean an improved binding of NGA to the same amount of
HBP-receptors. In parallel, the estimated RFLV via
S.P.E.C.T.-study was not significantly increased, although
improved. This result might be a consequence of the small
number of patients in whom a second evaluation could be
performed, as in general a good correlation between
S.P.E.C.T.-estimated RFLV and dynamic imaging of NGA-
binding was found. It should be mentioned that the threshol-
ding technique as such (Tauxe et al., 1982; Strauss et al.,
1984) is known to give accurate values especially for the
determination of liver volume due to negligible background
activity. The thresholding method used to determine the
RFLV from the S.P.E.C.T. images implies that large deposits
within the liver are excluded from the functional volume
evaluation. Small lesions that do not resolve on the trans-
verse slices of the S.P.E.C.T.-study can not be excluded from
the evaluation. These might 'dilute' the true RFLV. We
believe, however, that the increased RFLV measured after
chemotherapy as compared to the RFLV before
chemotherapy is not a side effect of such a possible dilution
effect, but represents a direct effect of (chemo)therapy on
liver metastases.554 I. VIRGOLINI et al.
In conclusion, 99Tc-NGA functional liver imaging may
provide a new noninvasive means for the selection of medical
or surgical management in patients with cancer. The changes
found in patients after amonafide treatment might suggest
the use for this technique in assessing chemotherapy. It
would be interesting to see whether this technique would
detect liver metastases before standard morphological studies
or laboratory liver function tests become abnormal. Deter-
mination of HBP activity with a highly specific tracer may
provide a valuable measure of hepatic injury and recovery,
and could thus provide further insights into receptor regula-
tion during disease states.
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